May 14, 2020
|
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
|
|
May 11, 2020
|
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
|
|
May 11, 2020
|
Vertex Foundation to Donate 10,000 Meals for Front-Line COVID-19 Health Care Workers at Two Boston Hospitals This Week
|
|
May 01, 2020
|
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
|
|
Apr 29, 2020
|
Vertex Reports First-Quarter 2020 Financial Results
|
|
Apr 28, 2020
|
Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials
|
|
Apr 27, 2020
|
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
|
|
Apr 24, 2020
|
The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response
|
|
Apr 21, 2020
|
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients
|
|
Apr 20, 2020
|
Vertex to Announce First-Quarter 2020 Financial Results on April 29
|
|
Apr 07, 2020
|
The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response
|
|
Apr 07, 2020
|
The Vertex Foundation Donates $300,000 to Support COVID-19 Relief Efforts in the Most Vulnerable Massachusetts Communities
|
|
Mar 27, 2020
|
Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs
|
|
Mar 13, 2020
|
The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response
|
|
Mar 09, 2020
|
Vertex Confirms Supply Chain Continuity and 2020 Business Outlook
|
|
Mar 02, 2020
|
Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference
|
|
Feb 25, 2020
|
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
|
|
Feb 25, 2020
|
Vertex to Present at the Cowen Health Care Conference on March 3
|
|
Jan 30, 2020
|
Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
|
|
Jan 21, 2020
|
Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30
|
|